Shanghai Tianhui Chemical Pharmaceutical

Shanghai Tianhui Chemical & Pharmaceutical Co., Ltd. is a pharmaceutical company based in Shanghai, China, specializing in the development of advanced drug delivery systems, particularly liposomal formulations. Founded in 2001, the company operates in close collaboration with the National Engineering Research Center for Pharmaceutical Preparations and is led by Executive Director Hou Jiong. Its primary therapeutic focus is oncology, with its lead pipeline candidate being a liposomal formulation of paclitaxel currently in Phase 1 clinical trials. This innovative formulation aims to improve the safety and tolerability of paclitaxel by reducing the risk of allergic reactions. Additionally, the company leverages its engineering expertise to produce pharmaceutical machinery and packaging materials.